Evaluation of nitazoxanide for the treatment of disseminated cystic echinococcosis: report of five cases and literature review.
Authors: Pérez-Molina JA,Díaz-Menéndez M,Gallego JI,Norman F,Monge-Maillo B,Ayala AP,López-Vélez R,
Address: Tropical Medicine, Infectious Diseases Department, Hospital Ramón y Cajal, IRICYS, Madrid, Spain. firstname.lastname@example.org
Journal: Am J Trop Med Hyg.
Publication: 2011 Feb;84(2):351-6. doi: 10.4269/ajtmh.2011.10-0513.
Free Text: Evaluation of nitazoxanide for the treatment of disseminated cystic echinococcosis: report of five cases and literature review.
We aimed to evaluate the effectiveness of nitazoxanide in disseminated cystic echinococcosis (DCE) that failed to respond to surgical and antiparasitic therapy. We report on seven patients (five of them with bony involvement): two cases from the literature and five patients who were included in a compassionate trial of nitazoxanide therapy in our hospital. Median follow-up time until nitazoxanide therapy was 12 years and all patients had received prior medical treatment and extensive surgery. Nitazoxanide (500 mg/12 h) in combination with albendazole, with/without praziquantel, was administered for 3-24 months. Three patients improved: one with muscle involvement (clinico-radiological response), one with lung involvement (radiological response), and another with soft tissue and bony involvement (clinico-radiological response of soft tissue cysts). There was one discontinuation after 15 days of starting therapy. Nitazoxanide combination therapy could have a role in the treatment of DCE when there is no bony involvement. Long-term safety profile seems to be favorable.
The contents within traveldoctoronline are presented only for informational purposes and cannot substitute for professional health care or any other medical treatment.All users of this website with health problems should be oblige always to consult their medical doctor before starting any treatment.